{"schema_version":"secwatch.filing_event.v1","accession":"0000926326-24-000012","form_type":"8-K","ticker":"OMCL","cik":"0000926326","company_name":"OMNICELL, INC.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.518784+00:00","generated_at":"2026-06-03T01:41:04.223886+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Omnicell Q1 revenues down 15% to $246M, GAAP net loss $0.34/sh; initiates wind-down of Medimat RDS","bullets":["Q1 GAAP revenues $246M (-15% YoY); GAAP net loss $16M ($0.34/sh) vs loss $15M ($0.33/sh) last year.","Non-GAAP net income $1M ($0.03/sh); non-GAAP EBITDA $11M, down from $27M in Q1 2023.","Management commits to wind down Medimat RDS product line; expects to cut >80 employees and close Bochum, Germany facility.","Estimated nonrecurring charges $15-20M ($10-13M cash); $1.6M impairment in Q4 2023 and $3.3M severance in Q1 2024 already recorded.","Full-year 2024 guidance unchanged: revenues $1.045-1.120B, non-GAAP EPS $0.90-1.40, non-GAAP EBITDA $90-120M."],"urls":{"canonical":"https://secwatch.observer/filing/0000926326-24-000012","json":"https://secwatch.observer/filing/0000926326-24-000012.json","markdown":"https://secwatch.observer/filing/0000926326-24-000012.md","text":"https://secwatch.observer/filing/0000926326-24-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926326/000092632624000012/0000926326-24-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926326/000092632624000012/omcl-20240426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T01:41:04.223886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e0e176f9a7a87247c92dca9e431abc3298c805b","claim":"OMNICELL, INC. reported first quarter ended March 31, 2024 results: revenue $246 million, net income $16 million, or $0.34 per diluted share, EPS $0.34 per diluted share.","evidence_excerpt":"Worth, TX 76137 Kathleen.Nemeth@Omnicell.com Omnicell Announces First Quarter 2024 Results Results exceed prior first quarter guidance across all metrics Total GAAP revenues of $246 million FORT WORTH, Texas -- May 2, 2024 -- Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy care","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926326/000092632624000012/0000926326-24-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$246 million"},{"label":"Net income","value":"$16 million, or $0.34 per diluted share"},{"label":"EPS","value":"$0.34 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"67bdc6bc3e56de255bd836b5d67f2447e991ddbe","claim":"OMNICELL, INC. announced a restructuring with charges of approximately $15 - $20 million affecting Medimat Robotic Dispensing System (RDS) product line (more than 80 employees).","evidence_excerpt":"once any required consent of the works council, as applicable, has finally been obtained. If the RDS Plan proceeds, the Company estimates that it will incur approximately $15 - $20 million of nonrecurring charges, of which $10 - $13 million are expected to result in future cash expenditures. The estimated nonrecurring charges consist of (i)","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/926326/000092632624000012/0000926326-24-000012-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $15 - $20 million"},{"label":"Affected area","value":"Medimat Robotic Dispensing System (RDS) product line"},{"label":"Headcount","value":"more than 80 employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}